CN104725472A - 芳香族阳离子肽及其用途 - Google Patents

芳香族阳离子肽及其用途 Download PDF

Info

Publication number
CN104725472A
CN104725472A CN201510081030.4A CN201510081030A CN104725472A CN 104725472 A CN104725472 A CN 104725472A CN 201510081030 A CN201510081030 A CN 201510081030A CN 104725472 A CN104725472 A CN 104725472A
Authority
CN
China
Prior art keywords
aromatic
peptide
lys
arg
dmt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510081030.4A
Other languages
English (en)
Chinese (zh)
Inventor
黑兹尔·H·司徒
彼得·W·席勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut de Recherches Cliniques de Montreal IRCM
Cornell University
Original Assignee
Institut de Recherches Cliniques de Montreal IRCM
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut de Recherches Cliniques de Montreal IRCM, Cornell University filed Critical Institut de Recherches Cliniques de Montreal IRCM
Publication of CN104725472A publication Critical patent/CN104725472A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201510081030.4A 2010-01-25 2011-01-24 芳香族阳离子肽及其用途 Pending CN104725472A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29806210P 2010-01-25 2010-01-25
US61/298,062 2010-01-25

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2011800071355A Division CN102834408A (zh) 2010-01-25 2011-01-24 芳香族阳离子肽及其用途

Publications (1)

Publication Number Publication Date
CN104725472A true CN104725472A (zh) 2015-06-24

Family

ID=44307257

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510081030.4A Pending CN104725472A (zh) 2010-01-25 2011-01-24 芳香族阳离子肽及其用途
CN2011800071355A Pending CN102834408A (zh) 2010-01-25 2011-01-24 芳香族阳离子肽及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2011800071355A Pending CN102834408A (zh) 2010-01-25 2011-01-24 芳香族阳离子肽及其用途

Country Status (8)

Country Link
US (6) US20120329730A1 (enExample)
EP (4) EP2733150A1 (enExample)
JP (2) JP2013518057A (enExample)
CN (2) CN104725472A (enExample)
AU (2) AU2011207432A1 (enExample)
CA (2) CA3008993A1 (enExample)
HK (1) HK1208686A1 (enExample)
WO (1) WO2011091357A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115160402A (zh) * 2016-03-11 2022-10-11 隐形生物治疗公司 结晶盐形式

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3150215A1 (en) * 2009-08-24 2017-04-05 Stealth Peptides International, Inc. Methods and compositions for preventing or treating opthalmic conditions
WO2011106717A1 (en) * 2010-02-26 2011-09-01 University Of Florida Research Foundation, Inc. Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP3560508A1 (en) 2010-03-15 2019-10-30 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
EP3290433A1 (en) * 2010-05-03 2018-03-07 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
CN102327600A (zh) * 2011-09-14 2012-01-25 中国人民解放军军事医学科学院放射与辐射医学研究所 用于预防和治疗辐射损伤的rx31肽
CN107496899A (zh) 2011-09-29 2017-12-22 梅约医学教育与研究基金会 芳族阳离子肽和使用它们的方法
EP2788013A4 (en) * 2011-12-09 2015-08-19 Stealth Peptides Int Inc AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
EP3170506B1 (en) * 2012-03-30 2018-05-16 Stealth Peptides International, Inc. Methods and compositions for the prevention and treatment neuropathy
WO2013155334A1 (en) * 2012-04-12 2013-10-17 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
PT2968443T (pt) 2013-03-15 2021-12-28 Protagonist Therapeutics Inc Análogos de hepcidina e seus usos
US20140294902A1 (en) * 2013-04-02 2014-10-02 Protagonist Therapeutics, Inc. Novel a4b7 peptide antagonists
CA2916492A1 (en) * 2013-06-27 2014-12-31 Stealth Biotherapeutics Corp Peptide therapeutics and methods for using same
US20160175379A1 (en) * 2013-08-12 2016-06-23 Stealth Bio Therapeutics Corp Combination therapy for the treatment of ischemia-reperfusion injury
EP3077049B1 (en) * 2013-12-02 2019-06-19 Stealth BioTherapeutics Corp Compositions for use in treating vitiligo
SG10201810321PA (en) 2014-05-16 2018-12-28 Protagonist Therapeutics Inc α4β7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS
ES2977537T3 (es) 2014-07-17 2024-08-26 Protagonist Therapeutics Inc Inhibidores peptídicos orales del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias intestinales
SG11201702553RA (en) 2014-10-01 2017-04-27 Protagonist Therapeutics Inc NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
CA2978905A1 (en) * 2015-03-06 2016-09-15 Stealth Biotherapeutics Corp Processes for preparing pharmaceutically relevant peptides
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP6533723B2 (ja) * 2015-09-11 2019-06-19 キユーピー株式会社 抗酸化剤
WO2017093897A1 (en) * 2015-11-30 2017-06-08 Peter Schiller Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
WO2017117411A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
WO2017117381A1 (en) * 2015-12-31 2017-07-06 Scott Duncan Therapeutic compositions including peptides and uses thereof
AU2017249218B2 (en) 2016-04-11 2020-08-27 Arcuate Therapeutics, Inc. Chiral peptides
US11034724B2 (en) 2017-04-05 2021-06-15 Stealth Biotherapeutics Corp. Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
EP4092038A1 (en) 2017-09-11 2022-11-23 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
EP4501952A3 (en) 2018-02-08 2025-04-16 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
JP7606966B2 (ja) * 2018-12-18 2024-12-26 ステルス バイオセラピューティクス インコーポレイテッド ミトコンドリア病を標的とするアナログ
EP3997105A4 (en) 2019-07-10 2023-09-13 Protagonist Therapeutics, Inc. PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES
IL294680A (en) 2020-01-15 2022-09-01 Janssen Biotech Inc Peptide inhibitors of the interleukin-23 receptor and their use for the treatment of inflammatory diseases
CN115279782A (zh) 2020-01-15 2022-11-01 詹森生物科技公司 白介素-23受体的肽抑制剂及其用于治疗炎性疾病的用途
IL302996B2 (en) 2020-11-20 2025-04-01 Janssen Pharmaceutica Nv Compositions of interleukin-23 receptor peptide inhibitors
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法
AU2022311814A1 (en) 2021-07-14 2024-02-29 Janssen Biotech, Inc. Lipidated peptide inhibitors of interleukin-23 receptor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004070054A2 (en) * 2003-02-04 2004-08-19 Cornell Research Foundation, Inc. Methods for preventing mitochondrial permeability transition
WO2005072295A2 (en) * 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
WO2009100363A2 (en) * 2008-02-07 2009-08-13 Cornell University Methods for preventing or treating insulin resistance
WO2009108695A2 (en) * 2008-02-26 2009-09-03 Cornell University Methods for prevention and treatment of acute renal injury

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0273696A2 (en) * 1987-01-02 1988-07-06 Merck & Co. Inc. Renin inhibitors containing histidine replacements
WO1991006563A1 (en) * 1989-11-06 1991-05-16 Farmitalia Carlo Erba S.R.L. Reduced irreversible bombesin antagonists
JPH06509075A (ja) * 1991-07-01 1994-10-13 ユニヴァーシティ　テクノロジーズ　インターナショナル　インコーポレイテッド ＧｎＲＨ及び他の生物学的に活性なリガンドの非感度低下性類縁体
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004070054A2 (en) * 2003-02-04 2004-08-19 Cornell Research Foundation, Inc. Methods for preventing mitochondrial permeability transition
WO2005072295A2 (en) * 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
WO2009100363A2 (en) * 2008-02-07 2009-08-13 Cornell University Methods for preventing or treating insulin resistance
WO2009108695A2 (en) * 2008-02-26 2009-09-03 Cornell University Methods for prevention and treatment of acute renal injury

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SZETO H H.: "Development of Mitochondria‐targeted Aromatic‐cationic Peptides for Neurodegenerative Diseases", 《 ANNALS OF THE NEW YORK ACADEMY OF SCIENCES》 *
SZETO H H: "Cell-permeable, mitochondrial-targeted, peptide antioxidants", 《DRUG ADDICTION》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115160402A (zh) * 2016-03-11 2022-10-11 隐形生物治疗公司 结晶盐形式

Also Published As

Publication number Publication date
US20180244721A1 (en) 2018-08-30
JP2013518057A (ja) 2013-05-20
WO2011091357A1 (en) 2011-07-28
AU2011207432A1 (en) 2012-08-02
EP3018138A1 (en) 2016-05-11
AU2016200747A1 (en) 2016-02-25
EP2528934A1 (en) 2012-12-05
US20150005242A1 (en) 2015-01-01
US20120329730A1 (en) 2012-12-27
EP2733150A1 (en) 2014-05-21
CN102834408A (zh) 2012-12-19
EP2848628A1 (en) 2015-03-18
JP2016000750A (ja) 2016-01-07
HK1208686A1 (en) 2016-03-11
EP2528934A4 (en) 2013-08-21
CA3008993A1 (en) 2011-07-28
CA2787331A1 (en) 2011-07-28
US20170008925A1 (en) 2017-01-12
US20130316964A1 (en) 2013-11-28
US20190330272A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
US20190330272A1 (en) Aromatic-cationic peptides and uses of same
CA2776581C (en) Methods for the prevention or treatment of heart failure
JP7072692B2 (ja) バース症候群の予防または治療のための方法及び組成物
CN116474071A (zh) 治疗线粒体疾病的方法
CN102791280A (zh) 用于预防或治疗血管阻塞损伤的方法
EP3049096B1 (en) Use of aromatic-cationic peptides to treat niemann-pick disease characterised by cholesterol-induced mitochondrial dysfunction
AU2017261638A1 (en) Aromatic-cationic peptides and uses of same
HK1179977A (en) Aromatic-cationic peptides and uses of same
HK1176561A (en) Methods for the prevention or treatment of heart failure

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1208686

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150624

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1208686

Country of ref document: HK